{"nct_id": "NCT05552976", "age": "Adults", "cancer_center_accrual_goal_upper": 0, "data_table4": "Interventional", "drug_list": {"drug": [{"drug_name": "Drug: Mezigdomide"}, {"drug_name": "Drug: Dexamethasone"}, {"drug_name": "Drug: Carfilzomib"}]}, "long_title": "A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2", "management_group_list": {"management_group": [{"is_primary": "Y", "management_group_name": "Group1"}]}, "oncology_group_list": {"oncology_group": [{"group_name": "Group1", "is_primary": "N"}]}, "phase": "PHASE3", "principal_investigator": "Bristol-Myers Squibb", "principal_investigator_institution": "Bristol-Myers Squibb", "program_area_list": {"program_area": [{"is_primary": "Y", "program_area_name": "Program1"}]}, "protocol_id": 0, "protocol_no": "", "protocol_target_accrual": 525, "protocol_type": "INTERVENTIONAL", "prior_treatment_requirements": ["Inclusion Criteria", "- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:.", "i) Myeloma-protein (M-protein) \u2265 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.", "ii) M-protein \u2265 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.", "iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels \\> 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal \u03ba/\u03bb free light chain ratio.", "* Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, \\[with or without\\] hematopoietic stem cell transplant, (with or without) consolidation, and/or \\[with or without\\] maintenance therapy).", "* Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received \\< 2 cycles are still eligible).", "* Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.", "* Participant must have documented disease progression during or after their last antimyeloma regimen.", "Exclude - Exclusion Criteria", "Exclude - * Participant who has had prior treatment with mezigdomide or carfilzomib.", "Exclude - * Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.", "Exclude - * Other protocol-defined Inclusion/Exclusion criteria apply."], "short_title": "A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)", "site_list": {"site": []}, "sponsor_list": {"sponsor": [{"is_principal_sponsor": "Y", "sponsor_name": "Bristol-Myers Squibb", "sponsor_protocol_no": "", "sponsor_roles": "sponsor"}]}, "staff_list": {"protocol_staff": []}, "status": "open to accrual", "summary": "The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.", "treatment_list": {"step": [{"arm": [{"arm_code": "MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)", "arm_internal_id": 0, "arm_description": {}, "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Mezigdomide", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Carfilzomib", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Dexamethasone", "level_internal_id": 2, "level_suspended": "N"}]}, {"arm_code": "Kd (Carfilzomib + Dexamethasone)", "arm_internal_id": 1, "arm_description": {}, "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Carfilzomib", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Dexamethasone", "level_internal_id": 1, "level_suspended": "N"}]}], "match": [{"and": [{"clinical": {"oncotree_primary_diagnosis": "", "disease_status": ["", ""]}}, {"genomic": {"hugo_symbol": "", "variant_category": ""}}]}]}]}}